Mesoblast Phase 3 Chronic Heart Failure Results
Filed with ASX · · 3 pages · English
Earlier from Mesoblast
- Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
- Novartis and Mesoblast Remestemcel-L Collaboration
- First Quarter Results Presentation
- DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
- COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
Later from Mesoblast
- Trading halt
- Mesoblast Update on COVID-19 ARDS Trial
- Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
- Mesoblast Phase 3 Chronic Low Back Pain Results
- Mesoblast Raises US$110M Led By US Strategic Investor Group
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast